Peregrine Capital Management LLC Lowers Stake in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Peregrine Capital Management LLC decreased its position in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 5.2% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 94,198 shares of the medical equipment provider's stock after selling 5,148 shares during the period. Peregrine Capital Management LLC owned approximately 0.14% of Lantheus worth $9,194,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of LNTH. Avantax Advisory Services Inc. lifted its stake in shares of Lantheus by 5.9% in the fourth quarter. Avantax Advisory Services Inc. now owns 2,382 shares of the medical equipment provider's stock worth $213,000 after buying an additional 132 shares in the last quarter. Foundry Partners LLC boosted its stake in Lantheus by 4.5% during the 4th quarter. Foundry Partners LLC now owns 3,103 shares of the medical equipment provider's stock valued at $278,000 after purchasing an additional 133 shares during the last quarter. Moody National Bank Trust Division boosted its stake in Lantheus by 1.0% during the 1st quarter. Moody National Bank Trust Division now owns 14,910 shares of the medical equipment provider's stock valued at $1,455,000 after purchasing an additional 141 shares during the last quarter. Aurora Investment Counsel increased its holdings in shares of Lantheus by 0.8% in the 4th quarter. Aurora Investment Counsel now owns 19,200 shares of the medical equipment provider's stock worth $1,718,000 after purchasing an additional 146 shares in the last quarter. Finally, Trueblood Wealth Management LLC raised its stake in shares of Lantheus by 1.4% in the first quarter. Trueblood Wealth Management LLC now owns 11,037 shares of the medical equipment provider's stock worth $1,077,000 after purchasing an additional 151 shares during the last quarter. 99.06% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Lantheus

In related news, Director Mary Anne Heino sold 26,066 shares of Lantheus stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $76.83, for a total transaction of $2,002,650.78. Following the transaction, the director directly owned 318,650 shares in the company, valued at approximately $24,481,879.50. The trade was a 7.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 2.00% of the stock is owned by company insiders.

Lantheus Stock Performance

NASDAQ:LNTH traded up $0.37 on Monday, hitting $81.86. The stock had a trading volume of 960,447 shares, compared to its average volume of 1,016,758. The business's 50-day simple moving average is $84.72 and its two-hundred day simple moving average is $90.67. The stock has a market cap of $5.66 billion, a price-to-earnings ratio of 23.26 and a beta of 0.11. Lantheus Holdings, Inc. has a 52-week low of $73.11 and a 52-week high of $126.89. The company has a quick ratio of 5.46, a current ratio of 5.74 and a debt-to-equity ratio of 0.49.

Lantheus (NASDAQ:LNTH - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.64 by ($0.11). Lantheus had a return on equity of 36.99% and a net margin of 16.55%. The business had revenue of $372.76 million during the quarter, compared to analysts' expectations of $377.37 million. During the same period in the previous year, the business posted $1.69 EPS. The business's quarterly revenue was up .8% compared to the same quarter last year. As a group, research analysts predict that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

Analyst Ratings Changes

LNTH has been the topic of several recent analyst reports. B. Riley dropped their price objective on Lantheus from $122.00 to $109.00 and set a "buy" rating on the stock in a research report on Monday, June 23rd. Truist Financial lowered their target price on shares of Lantheus from $127.00 to $117.00 and set a "buy" rating on the stock in a research note on Thursday, May 8th. Finally, Wall Street Zen upgraded shares of Lantheus from a "hold" rating to a "buy" rating in a research note on Thursday, May 8th. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of "Buy" and an average target price of $130.50.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.